Document is current
Any future updates will be listed below
-
Authors
LeBlanc, Danielle P. M. https://orcid.org/0000-0002-3847-8371
Meier, Matthew https://orcid.org/0000-0001-8199-8754
Lo, Fang Yin https://orcid.org/0000-0002-8974-6508
Schmidt, Elizabeth https://orcid.org/0000-0001-9572-8368
Valentine, Charles III https://orcid.org/0000-0001-5630-7368
Williams, Andrew https://orcid.org/0000-0002-7637-7686
Salk, Jesse J. https://orcid.org/0000-0002-7804-0550
Yauk, Carole L. https://orcid.org/0000-0002-6725-3454
Marchetti, Francesco https://orcid.org/0000-0002-9435-4867
- License Information
-
More Information
Article History
Received: 5 April 2022
Accepted: 4 July 2022
First Online: 28 July 2022
Declarations
:
: The use and handling of laboratory animals in this study was approved by the Health Canada Ottawa Animal Care Committee under protocol 2013–010 and methods carried out in compliance with relevant guidelines and regulations. We confirm that all methods are reported in accordance with ARRIVE guidelines.
: Not applicable.
: D.P.M.L., M.M., A.W., C.L.Y. and F.M. declare that they have no completing interests.F.Y.L., E.S, C.V., and J.J.S. declare that they are employees and equity holders at TwinStrand Biosciences, Inc. and are authors on one or more Duplex Sequencing-related patents.
